Amplia Therapeutics and ANZGOG Announce Ovarian Cancer Clinical Study

Amplia Therapeutics and the Australia New Zealand Gynaecological Oncology Group (ANZGOG) have announced a clinical study to evaluate narmafotinib, a FAK inhibitor, in combination with standard chemotherapy for ovarian cancer. The trial, led by Dr. Gwo Yaw Ho, aims to enroll 15–20 patients with high-grade serous ovarian cancer who have not responded well to platinum-based chemotherapy prior to surgery.

By Amplia Therapuetics Limited · GlobeNewsWire · May 9, 2026, 00:45 UTC

Topics: ANZGOG clinical trial FAK inhibition narmafotinib ovarian cancer

Read the full article at GlobeNewsWire

More World news

The Adecco Group Reports Q3 2026 Growth Driven by Temporary Staffing and Margin Expansion PR Newswire · November 12, 2026, 18:54 UTC
Twist Bioscience Projects FY2027 Revenue Between $550M and $560M Seeking Alpha · November 12, 2026, 18:50 UTC
Dixie Group Reports Q3 Sales Growth Amid Margin Pressure and Future Cost-Reduction Targets Seeking Alpha · November 12, 2026, 18:50 UTC
Data I/O Corporation Targets Rapid V-TEK Synergy Realization Amid $80 Million M&A Pipeline Seeking Alpha · November 12, 2026, 18:50 UTC
Leatt Corporation Reports 43% Increase in Q3 Revenue to $20.46 Million Seeking Alpha · November 12, 2026, 18:50 UTC
Parsons Reports Strong Third Quarter Results Driven by High-Margin Product Shift Motley Fool · November 12, 2026, 18:45 UTC
C.H. Robinson Reports Q3 2026 Earnings Driven by AI Efficiency and Margin Expansion Motley Fool · November 12, 2026, 18:45 UTC
Baker Hughes Raises Guidance Amid Surging Data Center Power Demand Motley Fool · November 12, 2026, 18:45 UTC
California Supreme Court to Rule on Insurance Overcharge Liability Under Proposition 103 PR Newswire · November 12, 2026, 18:44 UTC
Federal Court Orders Veterans Guardian to Pay Treble Damages to Disabled Veteran Class PR Newswire · November 12, 2026, 18:41 UTC